Women’s health company Hologic (HOLX) was hit by a series of downgrades Tuesday morning after its quarterly revenue and guidance missed estimates, sending shares down 14% to below 20 in the stock market, a four-month low. Late Monday, Hologic reported sales for its fiscal Q4 ended Sept. 28 of $622.1 million, up 6% from the year-earlier quarter but about $2 million short of analysts’ consensus. Profit rose 5% to 39 cents a share, beating views by 2
Read the original post:
Hologic Downgraded After 2014 Guidance Misses Street